Aa
Aa
A
A
A
Close
4309115 tn?1357606283

You don't need 20 grms af fat for telepravir

Many times I questioned the clinic nurse And the treating Doctor and they both said it just needs to be taken,with a tall gglass full cream milk or a couple of tablespoons of full cream yougurt,so what has antyone else been told they have to strickly take 20gms of fat.a sI was told that is not the case.
Best Answer
Avatar universal
I believe it is very important to follow the instructions. I took 2 TBS of macadamia nut oil instead of the food fat. It worked for me!  
48 Responses
Sort by: Helpful Oldest Newest
1747881 tn?1546175878
Straight out of janssens incivo booklet

http://www.medhelp.org/user_photos/show/308364?personal_page_id=2257209

http://www.hepcnomads.co.uk/Incivo/Diet_and_Lifestyle_Booklet_incivo.pdf
Helpful - 0
Avatar universal
Wow....40 posts  on what to take Inci with ?

  Possibly try 20 grams of fat for best results. (as per instuctions) as HPG has said...


Will
Helpful - 0
1747881 tn?1546175878
I guess anything is worth a shot, but if you fail with these drugs, you can't just go back and follow the instructions :) So my advice to all is to follow the instructions.

Have a great day
Helpful - 0
Avatar universal
FYI, Me taking the pills with whole milk was not that I took a "risk" or just got lucky. This came from a leading Hepatologist in Boston. I wasn't able to keep the pills down with fat. Taking with milk was an "alternative" that worked.

I'm not suggesting for anyone to take with just milk. But rather then not taking them at all you can drink milk instead.

Actually with this resilient virus I will take some luck as well :-)
Helpful - 0
3093770 tn?1389739126

Yep, this one is from 2012, not sure why they needed to repeat it (and they do have different results as well, lower than the ones you have posted and probably morea realistic. Still, 74% is good :)

Janssen Research & Development Infectious Diseases - Diagnostics BVBA (Janssen) will present results from the OPTIMIZE Phase 3 trial for INCIVO® (telaprevir), during a late-breaking poster presentation at the 63rd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston (http://www.aasld.org/lm2012). The study, which was completed in September, investigates the efficacy and safety of the twice-daily dosing (BID) of telaprevir versus dosing every eight hours (q8h) in people chronically infected with genotype-1 hepatitis C virus (HCV) who had not been previously treated.[1]


The results demonstrated that BID dosing of telaprevir 1,125mg in combination with peginterferon alfa and ribavirin (PR), achieved similar cure rates, also known as sustained virological response (SVR12) to q8h dosing of telaprevir 750mg (74.3% versus 72.8%), thereby meeting its primary objective of non-inferiority versus q8h dosing.[1] The safety and tolerability of telaprevir was comparable across dosing arms and consistent with previous studies. The most common adverse events experienced were fatigue, pruritus, anemia, nausea and rash.[
Helpful - 0
1747881 tn?1546175878
Study C208 explored telaprevir-based regimens dosed either every 12 hours (q12h; twice daily) or every eight hours (q8h; three times daily) combined with either peg-IFN-alfa-2a (PEGASYS(R)) or peg-IFN-alfa-2b (PEGINTRON(R)) and ribavirin (RBV), for 12 weeks followed by an additional 12 weeks of peg-IFN and RBV in a response-guided trial design that included 161 treatment-naïve patients (intent-to-treat analysis) with genotype 1 hepatitis C virus (HCV) infection. Across the four arms, SVR rates were 82 and 83 percent in patients treated with the every 12 hour telaprevir-based regimen (PEGINTRON and PEGASYS, respectively) and 81 and 85 percent in patients treated with the every 8 hour regimen (PEGINTRON and PEGASYS, respectively). For the majority of patients, these SVR rates were obtained with a 24-week telaprevir-based regimen.

"With high SVR rates and similar safety outcomes between the twice-daily and three-times-daily treatment groups, the results from this exploratory study support the future evaluation of telaprevir-based regimens dosed twice daily," said Professor Patrick Marcellin, M.D., from Beaujon Hospital in Clichy, France. "These results also highlight the potential future role for response-guided therapy with the goal of improving treatment outcomes and potentially shortening the duration of therapy for the majority of patients."

Study C208 Results                         RVR* SVR**
TVR (q12h/peg-IFN alfa-2a/RBV) (n=40)  83% (n=33)        83% (n=33)
TVR (q12h/peg-IFN alfa-2b/RBV) (n=39)  67% (n=26)     82% (n=32)
TVR (q8h/peg-IFN alfa-2a/RBV) (n=40)    80% (n=32)     85% (n=34)
TVR (q8h/peg-IFN alfa-2b/RBV) (n=42)    69% (n=29)     81% (n=34)

* Rapid Viral Response: Undetectable HCV RNA at week 4

** Sustained Viral Response: Undetectable HCV RNA 24 weeks after the end of treatment

alfa-2a: PEGASYS

alfa-2b: PEGINTRON

(cont) at the following link

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=420611
Helpful - 0
Have an Answer?

You are reading content posted in the Hepatitis C Community

Top Hepatitis Answerers
317787 tn?1473358451
DC
683231 tn?1467323017
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.